10.85

2.86% -0.32

After Hours: 10.81 -0.04 -0.37%

INmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

INmune Bio Inc stock is currently priced at $10.85, with a 24-hour trading volume of 84,727. It has seen a -2.86% decreased in the last 24 hours and a +28.71% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $11.19 pivot point. If it approaches the $10.68 support level, significant changes may occur.

Previous Close:

$11.17

Open:

$11.36

24h Volume:

84,727

Market Cap:

$214.64M

Revenue:

$155.00K

Net Income/Loss:

$-30.01M

P/E Ratio:

-7.1382

EPS:

-1.52

Net Cash Flow:

$-11.98M

1W Performance:

+8.28%

1M Performance:

+28.71%

6M Performance:

+46.42%

1Y Performance:

+46.42%

1D Range:

$10.76

$11.36

52W Range:

$6.5001

$14.74

INmune Bio Inc Stock (INMB) Company Profile

Name

INmune Bio Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

858-964-3720

Address

1224 Prospect Street, Suite 150, La Jolla, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2024-05-31

Latest SEC Filings

INMB's Discussions on Twitter

INmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

INmune Bio Inc Stock (INMB) Latest News

Inmune Bio Inc Grants Stock Options to Top Executives - TipRanks.com - TipRanks

TipRanks

INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Earnings call: INmune Bio optimistic on XPro and INKmune trials progress - Investing.com India

Investing.com India

INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Yahoo Finance

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update - 09.05.2024 - wallstreet:online

wallstreet:online

INmune Bio Inc Stock (INMB) Financials Data

INmune Bio Inc (INMB) Revenue 2024

INMB reported a revenue (TTM) of $155.00 thousand for the quarter ending December 31, 2023, a -58.56% decline year-over-year.

INmune Bio Inc (INMB) Net Income 2024

INMB net income (TTM) was -$30.01 million for the quarter ending December 31, 2023, a -9.92% decrease year-over-year.

INmune Bio Inc (INMB) Cash Flow 2024

INMB recorded a free cash flow (TTM) of -$11.98 million for the quarter ending December 31, 2023, a +47.19% increase year-over-year.

INmune Bio Inc (INMB) Earnings per Share 2024

INMB earnings per share (TTM) was -$1.67 for the quarter ending December 31, 2023, a -9.87% decline year-over-year.

INmune Bio Inc Stock (INMB) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Schroeder Timothy j	Director	Jul 12 '23	Sale	11.01	10,000	110,085	82,187

INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.